| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2015: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
|
|---|
| Outline of Final Research Achievements |
The platinum concentrations in plasma in 5 and 10 minutes after administration were 0.59±0.28μg/ml and 0.70±0.078μg/ml for the thrombin group, respectively, and 2.7±1.2μg/ml and 2.2±0.58μg/ml for the control group, respectively. At both 5 and 10 min after infusion, the platinum concentrations in plasma for the thrombin group were significant lower than that for the control group.
The platinum concentration in tumor tissue was 4.1±1.8 μg/wet・g for the thrombin group and 1.0±1.2μg/wet・g for the control group. The platinum concentration in tumor tissue for the thrombin group was significantly higher than that for the control group.
The present results suggest that transarterial infusion with thrombin may have a number of pharmacological advantages.
|
